California State Teachers Retirement System Sells 28,471 Shares of Johnson & Johnson $JNJ

Key Points

• CalSTRS trimmed its Johnson & Johnson stake by 0.8%, selling 28,471 shares in the second quarter but retaining 3.71 million shares worth approximately $943.5 million. Institutional investors collectively own 69.55% of J&J.
• Johnson & Johnson reported better-than-expected quarterly results, with adjusted EPS of $2.90 and revenue of $25.31 billion, while revenue increased 6.6% year over year. The company reaffirmed fiscal 2026 EPS guidance of $11.60–$11.75 and declared a quarterly dividend of $1.34 per share.
• Analysts remain broadly positive, with a “Moderate Buy” consensus and an average price target of $274.13. However, insider selling, a failed mid-stage depression-drug trial, and anticipated biosimilar competition for STELARA remain risks.

California State Teachers Retirement System trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 0.8% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,714,961 shares of the company's stock after selling 28,471 shares during the period. Johnson & Johnson makes up 0.9% of California State Teachers Retirement System's investment portfolio, making the stock its 26th largest holding. California State Teachers Retirement System owned 0.15% of Johnson & Johnson worth $943,488,645 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Ameritas Advisory Services LLC boosted its stake in Johnson & Johnson by 105.7% during the second quarter. Ameritas Advisory Services LLC now owns 25,667 shares of the company's stock worth $6,519,000 after buying an additional 13,188 shares during the period. Guardian Wealth Advisors LLC NC grew its holdings in shares of Johnson & Johnson by 1.1% during the second quarter. Guardian Wealth Advisors LLC NC now owns 9,997 shares of the company's stock valued at $2,539,000 after purchasing an additional 104 shares during the last quarter. Henrickson Nauta Wealth Advisors Inc. grew its stake in shares of Johnson & Johnson by 27.6% in the 2nd quarter. Henrickson Nauta Wealth Advisors Inc. now owns 2,309 shares of the company's stock worth $586,000 after purchasing an additional 499 shares during the last quarter. Kintra Wealth LLC increased its position in Johnson & Johnson by 7.8% in the 2nd quarter. Kintra Wealth LLC now owns 32,918 shares of the company's stock worth $8,627,000 after purchasing an additional 2,374 shares during the last quarter. Finally, PCG Wealth Advisors LLC grew its position in Johnson & Johnson by 29.3% during the second quarter. PCG Wealth Advisors LLC now owns 1,193 shares of the company's stock worth $303,000 after buying an additional 270 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Down 0.2%

JNJ stock traded down $0.55 during mid-day trading on Tuesday, hitting $265.77. 2,351,552 shares of the company were exchanged, compared to its average volume of 8,039,338. The firm's 50 day simple moving average is $263.18 and its 200 day simple moving average is $246.08. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The firm has a market cap of $640.47 billion, a P/E ratio of 30.78, a P/E/G ratio of 2.54 and a beta of 0.24. Johnson & Johnson has a 1-year low of $173.33 and a 1-year high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm's quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were given a dividend of $1.34 per share. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. Johnson & Johnson's payout ratio is currently 62.11%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of the firm's stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the sale, the executive vice president owned 23,003 shares of the company's stock, valued at $5,779,963.81. This trade represents a 50.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 87,569 shares of company stock valued at $23,064,544 over the last three months. Insiders own 0.16% of the company's stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Rybrevant data strengthens J&J’s oncology growth story. Final Phase 3 PAPILLON results showed Rybrevant plus chemotherapy delivered median overall survival of 34.3 months in patients with EGFR exon 20 insertion-positive lung cancer—the longest reported result for this population. Additional Phase 2b COPERNICUS data showed low rates of rash, blood clots and administration-related reactions for subcutaneous Rybrevant Faspro plus Lazcluze, with fewer than 1% of patients discontinuing treatment because of treatment-related events. These results could support broader adoption and sales growth. Rybrevant Faspro and Lazcluze WCLC 2026 results
• Positive Sentiment: Analyst support and a possible DePuy Synthes transaction are adding a catalyst. TD Cowen maintained a Buy rating and a $300 price target, citing oncology momentum and the possibility that J&J could sell or spin off its DePuy Synthes orthopedics unit for roughly $20 billion. A transaction could unlock value and sharpen J&J’s focus on pharmaceuticals and medical technology. TD Cowen J&J rating
• Neutral Sentiment: J&J’s defensive profile remains attractive to income-oriented investors. Articles highlighted the company’s dividend reliability and its appeal as a defensive stock amid concerns about AI-related risks weighing on technology shares. However, these themes are unlikely to materially change near-term earnings expectations. J&J dividend-stock analysis
• Negative Sentiment: A partnered depression drug failed its mid-stage trial. Contineum reported that J&J-partnered JNJ-5120, also known as PIPE-307, failed to meet the primary endpoint in the Phase 2 MOONLIGHT-1 depression study. J&J is reviewing additional data, but the setback removes or delays a potential neuroscience growth opportunity and contributed to weakness in Contineum shares. Contineum and J&J depression-drug trial report
• Negative Sentiment: Investors continue to monitor portfolio and pricing risks. J&J is targeting double-digit growth despite upcoming biosimilar competition for STELARA, while its requirement that providers share claims data to receive 340B discounts could attract additional scrutiny from hospitals and policymakers. J&J growth and STELARA competition report

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley upped their target price on shares of Johnson & Johnson from $284.00 to $294.00 and gave the company an "overweight" rating in a report on Thursday, July 16th. Bank of America lifted their target price on shares of Johnson & Johnson from $254.00 to $263.00 and gave the company a "neutral" rating in a research note on Friday, July 10th. Weiss Ratings raised shares of Johnson & Johnson from a "buy (b-)" rating to a "buy (b)" rating in a report on Friday, July 24th. HSBC lifted their target price on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a "buy" rating in a research note on Thursday, September 10th. Finally, TD Cowen lifted their target price on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a "buy" rating in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $274.13.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.